DE69804659D1 - 21-hydro-6,19-oxidoprogesterone (21oh-60p) und deren verwendung als arzneimittel zur behandlung von glukokortikoidüberschuss - Google Patents

21-hydro-6,19-oxidoprogesterone (21oh-60p) und deren verwendung als arzneimittel zur behandlung von glukokortikoidüberschuss

Info

Publication number
DE69804659D1
DE69804659D1 DE69804659T DE69804659T DE69804659D1 DE 69804659 D1 DE69804659 D1 DE 69804659D1 DE 69804659 T DE69804659 T DE 69804659T DE 69804659 T DE69804659 T DE 69804659T DE 69804659 D1 DE69804659 D1 DE 69804659D1
Authority
DE
Germany
Prior art keywords
oxidoprogesterone
glucocortico
hydro
medicine
excess
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69804659T
Other languages
English (en)
Other versions
DE69804659T2 (de
Inventor
Gerardo Burton
Pedro Lantos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Applied Research Systems ARS Holding NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems ARS Holding NV filed Critical Applied Research Systems ARS Holding NV
Publication of DE69804659D1 publication Critical patent/DE69804659D1/de
Application granted granted Critical
Publication of DE69804659T2 publication Critical patent/DE69804659T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69804659T 1997-09-23 1998-09-22 21-hydro-6,19-oxidoprogesterone (21oh-60p) und deren verwendung als arzneimittel zur behandlung von glukokortikoidüberschuss Expired - Fee Related DE69804659T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97116526A EP0903146A1 (de) 1997-09-23 1997-09-23 21-Hydroy-6,19-oxidoprogesterone (21-0H-60P) als ANitoglucocortikoid
PCT/EP1998/006021 WO1999015181A1 (en) 1997-09-23 1998-09-22 21-hydroxy-6,19-oxidoprogesterone (21oh-6op) and its use as medicament for treating excess of glucocorticoids

Publications (2)

Publication Number Publication Date
DE69804659D1 true DE69804659D1 (de) 2002-05-08
DE69804659T2 DE69804659T2 (de) 2002-10-02

Family

ID=8227390

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69804659T Expired - Fee Related DE69804659T2 (de) 1997-09-23 1998-09-22 21-hydro-6,19-oxidoprogesterone (21oh-60p) und deren verwendung als arzneimittel zur behandlung von glukokortikoidüberschuss

Country Status (13)

Country Link
US (1) US6303591B1 (de)
EP (2) EP0903146A1 (de)
AR (1) AR023008A1 (de)
AT (1) ATE215373T1 (de)
AU (1) AU738522B2 (de)
CA (1) CA2303817C (de)
DE (1) DE69804659T2 (de)
DK (1) DK1033990T3 (de)
ES (1) ES2172937T3 (de)
IL (1) IL135232A (de)
PT (1) PT1033990E (de)
WO (1) WO1999015181A1 (de)
ZA (1) ZA988674B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1542A (en) 1999-04-30 2006-01-31 Pfizer Prod Inc Glucocorticoid receptor modulators.
US7713989B2 (en) 2000-04-27 2010-05-11 Dow Robert L Glucocorticoid receptor modulators
PT1330468E (pt) 2000-09-18 2007-09-13 Serono Lab Análogos de enxofre de 21-hidroxi-6, 19-oxidoprogesterona ( 21oh-60p) para tratar excesso de glucocorticóides.
SI1325022T1 (sl) * 2000-09-18 2007-04-30 Applied Research Systems Metoda za pripravo 21-hidroksi-6,19-oksidoprogesterona (21oh-6op)
ES2246292T3 (es) 2000-10-30 2006-02-16 Pfizer Products Inc. Moduladores de receptor glucocorticoide.
US8097606B2 (en) * 2003-07-23 2012-01-17 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of catatonia
EP1886695A1 (de) * 2006-06-27 2008-02-13 Speedel Experimenta AG Pharmazeutische Kombinationen mit einem Aldosteron Synthasehemmer und Glucocorticoid Rezeptorantagonisten oder Cortisol Synthasehemmer oder Corticotropin Releasing Faktor Antagonisten
DK2054049T3 (en) 2006-08-24 2016-08-01 Univ Tennessee Res Found SUBSTITUTED ACYLANILIDES AND PROCEDURES FOR USING THEREOF
US11103514B2 (en) * 2010-05-26 2021-08-31 Corcept Therapeutics, Inc. Treatment of muscular dystrophy
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
KR102238970B1 (ko) 2012-07-13 2021-04-09 지티엑스, 인코포레이티드 선택적 안드로겐 수용체 조절자(sarms)를 이용한 안드로겐 수용체(ar) 양성 유방암의 치료 방법
EP3265127B1 (de) 2015-03-02 2024-02-21 Corcept Therapeutics, Inc. Mifepriston und octreotid zur verwendung bei der behandlung des cushing-syndroms bei einem patienten mit einem adrenocorticotropen hormon (acth) sezernierenden pankreatischen neuroendokrinen tumor
ES2906778T3 (es) 2015-03-30 2022-04-20 Corcept Therapeutics Inc Uso de antagonistas del receptor de glucocorticoides en combinación con glucocorticoides para tratar la insuficiencia suprarrenal
JP6768789B2 (ja) 2015-08-13 2020-10-14 コーセプト セラピューティクス， インコーポレイテッド Ａｃｔｈ依存性クッシング症候群を鑑別診断する方法
EP3405101B1 (de) 2016-01-19 2020-12-23 Corcept Therapeutics, Inc. Differentialdiagnose von ektopischem cushing-syndrom
EP3641780A4 (de) 2017-06-20 2021-02-24 Corcept Therapeutics, Inc. Verfahren zur behandlung von neuroepitheltumoren unter verwendung selektiver glucocorticoidrezeptormodulatoren
AU2019414333A1 (en) * 2018-12-28 2021-08-05 Panda Consulting Llc Short-acting selective glucocorticoid receptor modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL118974A (en) * 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
WO1999017779A1 (en) * 1997-10-06 1999-04-15 The Board Of Trustees Of Leland Stanford Jr. University Methods for treating psychosis associated with glucocorticoid related dysfunction

Also Published As

Publication number Publication date
ES2172937T3 (es) 2002-10-01
AR023008A1 (es) 2002-09-04
WO1999015181A1 (en) 1999-04-01
CA2303817C (en) 2008-04-01
EP1033990A1 (de) 2000-09-13
AU738522B2 (en) 2001-09-20
AU1334199A (en) 1999-04-12
PT1033990E (pt) 2002-07-31
DE69804659T2 (de) 2002-10-02
EP1033990B1 (de) 2002-04-03
DK1033990T3 (da) 2002-07-08
CA2303817A1 (en) 1999-04-01
IL135232A (en) 2005-05-17
IL135232A0 (en) 2001-05-20
US6303591B1 (en) 2001-10-16
EP0903146A1 (de) 1999-03-24
ATE215373T1 (de) 2002-04-15
ZA988674B (en) 1999-06-28

Similar Documents

Publication Publication Date Title
DE69804659T2 (de) 21-hydro-6,19-oxidoprogesterone (21oh-60p) und deren verwendung als arzneimittel zur behandlung von glukokortikoidüberschuss
DE122009000052I2 (de) N-((1,2,4)triazoloazinyl)benzolsulfonamid- und pyridinsulfonamidverbindungen und deren verwendung als herbizide
ATE204754T1 (de) Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie
DE69710095D1 (de) Pharmazeutische zubereitung zur behandlung von diabetes
DE60013859D1 (de) Indolderivate und deren verwendung zur behandlung von u.a. osteoporosis
DE122007000002I2 (de) Pharmazeutische Zubereitung zur Verwendung in der Behandlung von Diabetes.
ATE438630T1 (de) 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
DE69519189D1 (de) Verschluss, Prozesskartusche und Bilderzeugungsgerät
ATE318138T1 (de) Pharmazeutisches mittel zur behandlung von diabetes
ATE238342T1 (de) Neue thrombin-inhibitoren, deren herstellung und verwendung
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
ATE273301T1 (de) Substituierte aza- und diazacycloheptan- und - cyclooctanverbindungen und deren verwendung
ATE227127T1 (de) Hochdosiertes chromtripicolinat zur behandlung von typ-ii-diabetes
ATE292975T1 (de) Verwendung von tetrahydolipstatin in der behandlung von diabetes typ ii
DE68910113D1 (de) Wachstuminhibierendes mittel und dessen verwendung.
DE69734296D1 (de) Neue dikaffeoylchinasäurederivate und deren verwendung zur behandlung von hepatitis b
DE69727240D1 (de) Kombinationen enthaltend vx478, zidovudin und 3tc zur behandlung von hiv
DE69716896D1 (de) Substituierte benzylamine-derivate und ihre verwendung zur behandlung von depression
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE69624214D1 (de) Hormonale medikamente und deren verwendung zur behebung von östrogenmangelerscheinungen
ATE264309T1 (de) Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren
DE69832722D1 (de) L-threonat-eisen, pharmazeutische zusammensetzung und verwendung zur verbesserung und behandlung von anämie bei menschen
TR199501553A2 (tr) Sefem bilesimleri ve bunlarin farmasötik olarak kullanilmasi.
DE69512965T2 (de) Metallorganische Verbindungen und deren Verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: LABORATOIRES SERONO S.A., COINSINS, VAUD, CH

8339 Ceased/non-payment of the annual fee